sarah.morrison said:

The line between titrate-through and stop is not severity, it is trajectory and what else is present.

I dislike how confidently this board tells people to push through. Incidence figures around 20 to 25% at the higher doses are class-typical, but the trials also had a discontinuation column, and "manageable with protocols" is not the same as manageable for everyone.

One concrete data point for the thread. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.

InsuranceTom said:

I dislike how confidently this board tells people to push through.

There is a second half to this that has not been said yet. The version of this that has an answer is narrower than the version being asked. Narrow it and it becomes tractable; leave it broad and the thread will produce nine confident and incompatible replies.

A narrower follow-up, since the general answer is now clear:

Whether holding at a lower dose for longer actually reduces total side-effect burden or just spreads it out?

OP back with an update, since a thread like this is useless without one.

Follow-up: smaller meals, less fat in the two days after dosing, and not lying down afterwards. Unglamorous, and it worked within a fortnight.